Christopher E. Kurtz

3.3k total citations · 1 hit paper
39 papers, 1.8k citations indexed

About

Christopher E. Kurtz is a scholar working on Surgery, Cardiology and Cardiovascular Medicine and Economics and Econometrics. According to data from OpenAlex, Christopher E. Kurtz has authored 39 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Surgery, 12 papers in Cardiology and Cardiovascular Medicine and 7 papers in Economics and Econometrics. Recurrent topics in Christopher E. Kurtz's work include Lipoproteins and Cardiovascular Health (27 papers), Health Systems, Economic Evaluations, Quality of Life (6 papers) and Cardiac pacing and defibrillation studies (5 papers). Christopher E. Kurtz is often cited by papers focused on Lipoproteins and Cardiovascular Health (27 papers), Health Systems, Economic Evaluations, Quality of Life (6 papers) and Cardiac pacing and defibrillation studies (5 papers). Christopher E. Kurtz collaborates with scholars based in United States, United Kingdom and Australia. Christopher E. Kurtz's co-authors include Narimon Honarpour, Marc S. Sabatine, Anthony Keech, Robert P. Giugliano, Terje R. Pedersen, Scott M. Wasserman, François Mach, Huei Wang, Peter S. Sever and Brian R. Ott and has published in prestigious journals such as New England Journal of Medicine, Circulation and Journal of the American College of Cardiology.

In The Last Decade

Christopher E. Kurtz

39 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cognitive Function in a Randomized Trial of Evolocumab

2017 329 citations Robert P. Giugliano, François Mach et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christopher E. Kurtz United States	19	1.3k	617	483	360	207	39	1.8k
Patrick M. Moriarty United States	18	1.3k 1.0×	394 0.6×	332 0.7×	349 1.0×	282 1.4×	40	1.7k
Lulu Ren Sterling United States	16	961 0.7×	419 0.7×	205 0.4×	368 1.0×	247 1.2×	21	2.2k
Daniel A. Gipe United States	13	1.7k 1.3×	736 1.2×	577 1.2×	573 1.6×	447 2.2×	24	2.1k
Roeland Huijgen Netherlands	23	1.2k 0.9×	341 0.6×	291 0.6×	470 1.3×	344 1.7×	44	1.5k
Garen Manvelian United States	21	1.2k 0.9×	228 0.4×	351 0.7×	178 0.5×	141 0.7×	55	1.7k
Marie T. Baccara‐Dinet France	27	2.6k 2.0×	409 0.7×	1.1k 2.4×	585 1.6×	390 1.9×	59	2.8k
Ian Bridges United Kingdom	12	1.3k 1.0×	195 0.3×	557 1.2×	321 0.9×	203 1.0×	31	1.5k
Imre Ungi Hungary	13	1.0k 0.8×	539 0.9×	196 0.4×	110 0.3×	105 0.5×	66	1.4k
Dick C.G. Basart Netherlands	8	819 0.6×	298 0.5×	177 0.4×	459 1.3×	250 1.2×	13	1.1k

Countries citing papers authored by Christopher E. Kurtz

Since Specialization

Citations

This map shows the geographic impact of Christopher E. Kurtz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher E. Kurtz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher E. Kurtz more than expected).

Fields of papers citing papers by Christopher E. Kurtz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher E. Kurtz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher E. Kurtz. The network helps show where Christopher E. Kurtz may publish in the future.

Co-authorship network of co-authors of Christopher E. Kurtz

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher E. Kurtz. A scholar is included among the top collaborators of Christopher E. Kurtz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher E. Kurtz. Christopher E. Kurtz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zimerman, André, Michelle L. O’Donoghue, Xinhui Ran, et al.. (2024). Long-Term Cognitive Safety of Achieving Very Low LDL Cholesterol with Evolocumab. NEJM Evidence. 4(1). EVIDoa2400112–EVIDoa2400112. 6 indexed citations

Zimerman, André, Michelle L. O’Donoghue, Xinhui Ran, et al.. (2023). Abstract 14714: Long-Term Neurocognitive Safety of LDL-C Lowering With Evolocumab: Open-Label Extension Data From FOURIER. Circulation. 148(Suppl_1). 2 indexed citations

Korthauer, Laura E., Robert P. Giugliano, Jianping Guo, et al.. (2022). No association between APOE genotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumab. PLoS ONE. 17(4). e0266615–e0266615. 7 indexed citations

Santos, Raúl D., Andrea Ruzza, G. Kees Hovingh, et al.. (2020). Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia. New England Journal of Medicine. 383(14). 1317–1327. 115 indexed citations

Teerlink, John R., Rafael Díaz, G. Michael Felker, et al.. (2020). BASELINE CHARACTERISTICS FROM THE CARDIOVASCULAR OUTCOMES TRIAL OF OMECAMTIV MECARBIL, GALACTIC-HF (GLOBAL APPROACH TO LOWERING ADVERSE CARDIAC OUTCOMES THROUGH IMPROVING CONTRACTILITY IN HEART FAILURE). Journal of the American College of Cardiology. 75(11). 754–754. 2 indexed citations

Gencer, Bariş, François Mach, Jianping Guo, et al.. (2020). Cognition After Lowering LDL-Cholesterol With Evolocumab. Journal of the American College of Cardiology. 75(18). 2283–2293. 63 indexed citations

Santos, Raúl D., Evan A. Stein, G. Kees Hovingh, et al.. (2020). Long-Term Evolocumab in Patients With Familial Hypercholesterolemia. Journal of the American College of Cardiology. 75(6). 565–574. 118 indexed citations

Gencer, Bariş, François Mach, Sabina A. Murphy, et al.. (2019). Abstract 13871: Evolocumab and Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: Analysis From FOURIER. Circulation. 1 indexed citations

Santos, Raúl D., G. Kees Hovingh, Dirk Blom, et al.. (2019). LONG-TERM EVOLOCUMAB USE IN SUBJECTS WITH HOMOZYGOUS AND SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: PRIMARY RESULTS OF THE TAUSSIG TRIAL. Journal of the American College of Cardiology. 73(9). 1715–1715. 3 indexed citations

10.

Baum, Seth J., Tiziana Sampietro, D. Datta, et al.. (2019). Effect of evolocumab on lipoprotein apheresis requirement and lipid levels: Results of the randomized, controlled, open-label DE LAVAL study. Journal of clinical lipidology. 13(6). 901–909.e3. 11 indexed citations

11.

Teerlink, John R., G. Michael Felker, John J.V. McMurray, et al.. (2019). EFFECT OF OMECAMTIV MECARBIL IN PATIENTS WITH ATRIAL FIBRILLATION AND HEART FAILURE WITH REDUCED EJECTION FRACTION: RESULTS FROM COSMIC-HF. Journal of the American College of Cardiology. 73(9). 691–691. 1 indexed citations

12.

Gaudet, Daniel, Gisle Langslet, Samuel S. Gidding, et al.. (2018). Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study. Journal of clinical lipidology. 12(5). 1199–1207. 21 indexed citations

13.

Murphy, Sabina A., Terje R. Pedersen, Zbigniew Gaciong, et al.. (2017). Abstract 15100: Reduction in Total Cardiovascular Events With the PCSK9 Inhibitor Evolocumab in Patients With Cardiovascular Disease in the FOURIER Trial. Circulation. 3 indexed citations

14.

Raal, Frederick J., G. Kees Hovingh, Dirk Blom, et al.. (2017). Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. The Lancet Diabetes & Endocrinology. 5(4). 280–290. 161 indexed citations

15.

Giugliano, Robert P., François Mach, Kenton H. Zavitz, et al.. (2017). Cognitive Function in a Randomized Trial of Evolocumab. New England Journal of Medicine. 377(7). 633–643. 329 indexed citations breakdown →

16.

Stein, Evan A., Michael J. Koren, Narimon Honarpour, et al.. (2015). CLINICAL EQUIVALENCE OF EVOLOCUMAB 140 MG EVERY TWO WEEKS AND 420 MG MONTHLY DOSING REGIMENS: A POOLED ANALYSIS OF 3146 PATIENTS IN PHASE 3 STUDIES. Journal of the American College of Cardiology. 65(10). A1368–A1368. 5 indexed citations

17.

Kiyosue, Arihiro, Narimon Honarpour, Christopher E. Kurtz, et al.. (2015). A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk. The American Journal of Cardiology. 117(1). 40–47. 91 indexed citations

18.

Leary, Peter J., et al.. (2012). Three‐Dimensional Analysis of Right Ventricular Shape and Function in Pulmonary Hypertension. Pulmonary Circulation. 2(1). 34–40. 44 indexed citations

19.

Kurtz, Christopher E. & Catherine M Otto. (2010). Aortic Stenosis. Medicine. 89(6). 349–379. 39 indexed citations

20.

Kurtz, Christopher E., Yariv Gerber, Susan A. Weston, et al.. (2006). Use of Ejection Fraction Tests and Coronary Angiography in Patients With Heart Failure. Mayo Clinic Proceedings. 81(7). 906–913. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact